Company names starting with "Q"

Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.

QOL Medical, LLC
Sucraid (Solution For Oral) (Oral) sacrosidase
NDA Applicant: QOL Medical, LLC BLA No.: 020772 Prod. No.: 001 Rx (1,003,000IU/118ML (8,500IU/ML)); 002 Rx (17,000IU/2ML (8,500IU/ML))

Exclusivity	Expiration	Exclusivity Description
Exclusivity Type: Orphan Drug Exclusivity	Apr 9, 2005	Orphan Designation: Treatment of congenital sucrase-isomaltase deficiency Approved Labeled Indication: Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.